Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study
2020/04/17 by Kathleen Weisel, Scott B. Berger, Scott Berger +10 · 25 citations
Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · Medicine · #Psoriasis: Treatment and Pathogenesis #NF-κB Signaling Pathways #Cytokine Signaling Pathways and Interactions
paper · pdf · doi:10.1002/cpt.1852
Abstract
Receptor-interacting protein kinase 1 (RIPK1), a regulator of inflammation and cell death, is a potential therapeutic target in immune-mediated inflammatory diseases (IMIDs). The objective of this phase IIa multicenter, randomized, double-blind, placebo-controlled study was to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and preliminary efficacy of GSK2982772, a RIPK1 inhibitor, in plaque-type psoriasis. Psoriasis patients (N = 65) were randomized to 60 mg twice daily (b.i.d.) or three times daily (t.i.d.), or placebo for 84 days. Most adverse events (AEs) were mild with no severe drug-related AEs reported. Plaque Lesion Severity Sum improved with b.i.d. treatment compared with placebo; interpretation of t.i.d. treatment results was complicated by a high placebo response. Reductions in epidermal thickness and infiltration by CD3+ T cells in the epidermis and dermis were observed compared with placebo. Results support the rationale for additional studies on RIPK1 inhibition in IMIDs.
Cited by
- Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. [europepmc]
- Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects. [europepmc]
- Targeting RIP Kinases in Chronic Inflammatory Disease. [europepmc]
- Airway epithelial cell necroptosis contributes to asthma exacerbation in a mouse model of house dust mite-induced allergic inflammation. [europepmc]
- The Role of the Key Effector of Necroptotic Cell Death, MLKL, in Mouse Models of Disease. [europepmc]
- Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772. [europepmc]
- Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis. [europepmc]
- A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. [europepmc]
- Chemogenomics for drug discovery: clinical molecules from open access chemical probes. [europepmc]
- Necroptosis in Pulmonary Diseases: A New Therapeutic Target. [europepmc]
- Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology. [europepmc]
- Interplay of Oxidative Stress and Necrosis-like Cell Death in Cardiac Ischemia/Reperfusion Injury: A Focus on Necroptosis. [europepmc]
- Necroptosis and Neuroinflammation in Retinal Degeneration. [europepmc]
- Cell death in skin function, inflammation, and disease. [europepmc]
- The role of RHIM in necroptosis. [europepmc]
- Targeting Necroptosis: A Novel Therapeutic Option for Retinal Degenerative Diseases. [europepmc]
- From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors. [europepmc]
- Targeting RIPK1 kinase for modulating inflammation in human diseases. [europepmc]
- Small-molecule discovery through DNA-encoded libraries. [europepmc]
- Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects. [europepmc]
- Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases. [europepmc]
- Saracatinib inhibits necroptosis and ameliorates psoriatic inflammation by targeting MLKL. [europepmc]
- Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. [europepmc]
- Cell death as an architect of adult skin stem cell niches. [europepmc]
- New strategies to enhance the efficiency and precision of drug discovery. [europepmc]
Related